OVARIAN CARCINOMA

This early-stage study tested a new cancer drug called PF-07820435, both alone and combined with an existing immunotherapy drug (sasanlimab), in people with advanced solid tumors. The main goals were to find safe doses and look for early signs that the treatment might help shrink…

This early-stage trial tested the safety and best dose of a new drug, STRO-002, when given with an existing cancer drug, bevacizumab. It was for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that had come back or stopped responding to standard treatme…

This early-stage study tested a personalized cancer treatment that modifies a patient's own immune cells to recognize and attack their specific tumor mutations. The trial enrolled 8 adults with advanced solid tumors (including ovarian, lung, pancreatic, and colorectal cancers) wh…

This early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…

This was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07826390. It was given alone or combined with another immunotherapy drug to people with advanced solid tumors that had spread or stopped responding to treatment. The main goal …